Cargando…

Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002–an antibody against COVID-19: a phase 1 clinical trial in healthy Chinese adults

BACKGROUND: The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and subsequent Coronavirus Disease 2019 (COVID-19) pandemic has resulted in a significant global public health burden, leading to an urgent need for effective therapeutic strategies. Monoclonal antibodies (mAbs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Guiling, Zhang, Ying, Wu, Kaiqi, Jin, Tinghan, Peng, Conggao, Jiang, Qi, Tian, Wenjuan, Chen, Zhong, Shen, Zhenwei, Sheng, Guoping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304326/ https://www.ncbi.nlm.nih.gov/pubmed/37370000 http://dx.doi.org/10.1186/s12879-023-08341-6

Ejemplares similares

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults
por: Chen, Guiling, et al.
Publicado: (2023)

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers
por: Li, Xiaojiao, et al.
Publicado: (2018)

The mechanism of the effects of Monascus jmbA rice on increased platelet count in Wistar rats infected with Dengue virus serotype 3
por: Triyono, Erwin Astha
Publicado: (2020)

Effect of Probenecid on Pharmacokinetics and Tolerability of Olmesartan in Healthy Chinese Volunteers()
por: Li, Kun-Yan, et al.
Publicado: (2014)

Evaluation of the safety, tolerability, and pharmacokinetics of RO7049389 in healthy Chinese volunteers
por: Wu, Xiaojie, et al.
Publicado: (2021)

A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men
por: Zhang, Hong, et al.
Publicado: (2021)

Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects
por: Chen, Hanjing, et al.
Publicado: (2022)

Corrigendum: Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta(®) in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers
por: Wu, Min, et al.
Publicado: (2022)

Single- and Multiple-Dose Trials to Determine the Pharmacokinetics, Safety, Tolerability, and Sex Effect of Oral Ginsenoside Compound K in Healthy Chinese Volunteers
por: Chen, Lulu, et al.
Publicado: (2018)

Safety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects
por: Xu, Junyu, et al.
Publicado: (2023)

Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers
por: Liu, Jian, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers
por: Li, Yingxin, et al.
Publicado: (2023)

Safety, Tolerability and Pharmacokinetics of Single-Dose Oral SYHA1402 in Healthy Chinese Subjects
por: Liang, Beibei, et al.
Publicado: (2023)

Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B‐Lymphocyte Stimulating Factor Receptor‐Antibody Fusion Protein, in Healthy Chinese Subjects
por: Xie, Jing, et al.
Publicado: (2022)

Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015)

Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
por: Fedyk, Eric R., et al.
Publicado: (2020)

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Intravenous Formulation of Meloxicam (QP001) in Healthy Chinese Subjects
por: Ma, Junlong, et al.
Publicado: (2023)

Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
por: Humeniuk, Rita, et al.
Publicado: (2023)

Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans
por: Nagy, Christa F., et al.
Publicado: (2017)

Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers
por: Nie, Shanshan, et al.
Publicado: (2022)

Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects
por: Sheng, Lei, et al.
Publicado: (2021)

The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives
por: Liu, Xin, et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
por: He, Xuemei, et al.
Publicado: (2022)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
por: Yang, Haijing, et al.
Publicado: (2022)

First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody
por: Ma, Tingting, et al.
Publicado: (2022)

Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, HEC30654, in Healthy Chinese Subjects
por: Li, Xiaojiao, et al.
Publicado: (2021)

A Phase 1, Randomized, Placebo‐Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men
por: Sakamoto, Kei, et al.
Publicado: (2020)

Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study
por: Li, Shanshan, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants
por: Cheung, Tommy Tsang, et al.
Publicado: (2023)

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study
por: Li, Yinjuan, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects
por: Roth, Karsten, et al.
Publicado: (2019)

LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA(®) in Chinese healthy male subjects
por: Cao, Guoying, et al.
Publicado: (2023)

Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects
por: Yang, Meng-Jie, et al.
Publicado: (2020)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
por: Monteith, David, et al.
Publicado: (2017)

Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects
por: Kim, Yu Kyong, et al.
Publicado: (2018)

Pharmacokinetics and tolerability of apremilast in healthy Korean adult men
por: Huh, Ki Young, et al.
Publicado: (2021)

Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers
por: Zou, Chan, et al.
Publicado: (2019)

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
por: Ruf, Peter, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_0uo4u7b8vlmrpdbfg3va17294i